Case 1: Discussion of Treatment Naïve nAMD With Aflibercept 8mg
David Eichenbaum, MD, FASRS discusses a case of exudative macular degeneration and opted for aflibercept 8 mg as treatment, which led to significant improvements in visual acuity and anatomical features.
Summary
David Eichenbaum, MD, FASRS discusses a case of exudative macular degeneration with sudden vision loss, a pigment epithelial detachment (PED), and subretinal fluid. In this case, the patient had access to various drugs, and the expert favored starting with one of the most modern and potent options, specifically aflibercept 8 mg or faricimab.
After initiating treatment with aflibercept 8 mg, the patient showed substantial improvements in both visual acuity and anatomical features. Following the third injection, he extended the interval to 8 weeks based on trial intervals and label recommendations. The patient's progress continued with each visit, demonstrated through the absence of subretinal fluid, complete flattening of the PED, and a well-preserved macular anatomy.
The case underscores the importance of individualized treatment choices, early drug access, and a shared decision-making approach between the physician and the patient.
This summary was AI-generated and edited for clarity.
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
